Enlarge image
Biontech headquarters in Mainz
Photo: UJ Alexander / imago images
The development of a coronavirus vaccine has brought the Mainz biotechnology company Biontech a solid increase in sales: For the past year, the Mainz biotechnology company expects sales of 482.3 million euros - after only around 108.6 million euros in the previous year.
The bottom line was a profit of 15 million euros.
So far, Biontech has shipped more than 200 million vaccine doses.
Orders for 1.4 million cans are on the books for 2021.
Now Biontech and its partner Pfizer want to produce more Covid-19 vaccine in 2021 than previously planned.
Biontech is now assuming a production capacity of up to 2.5 billion vaccine doses, announced the Mainz biotech company.
Most recently, the two partners had raised their production target to 2.3 to 2.4 from the previous two billion cans.
The increase was mainly made possible by improved manufacturing processes, the new Biontech production facility in Marburg, the approval of the withdrawal of a sixth vaccination dose and the expansion of the manufacturer and supplier network.
Biontech is holding further discussions with potential partners.
As of March 23, more than 200 million doses of the vaccine had been delivered worldwide.
More soon on SPIEGEL.de
apr / Reuters